A Phase III study of SPK-8011 for hemophilia A
Phase of Trial: Phase III
Latest Information Update: 19 Feb 2019
Price : $35 *
At a glance
- Drugs SPK 8011 (Primary)
- Indications Haemophilia A
- Focus Therapeutic Use
- Sponsors Spark Therapeutics
- 19 Feb 2019 Status changed from planning to recruiting, according to the Spark Therapeutics media release.
- 02 Dec 2018 According to a Spark Therapeutics media release, the company intends to initiate this phase 3 run-in study by the end of 2018 to collect prospective observational data on trial participants.
- 20 Aug 2018 New trial record